Literature DB >> 27913546

Diagnosing von Willebrand disease: genetic analysis.

Anne Goodeve1.   

Abstract

Investigation of a patient with possible von Willebrand disease (VWD) includes a range of phenotypic analyses. Often, this is sufficient to discern disease type, and this will suggest relevant treatment. However, for some patients, phenotypic analysis does not sufficiently explain the patient's disorder, and for this group, genetic analysis can aid diagnosis of disease type. Polymerase chain reaction and Sanger sequencing have been mainstays of genetic analysis for several years. More recently, next-generation sequencing has become available, with the advantage that several genes can be simultaneously analyzed where necessary, eg, for discrimination of possible type 2N VWD or mild hemophilia A. Additionally, several techniques can now identify deletions/duplications of an exon or more that result in VWD including multiplex ligation-dependent probe amplification and microarray analysis. Algorithms based on next-generation sequencing data can also identify missing or duplicated regions. These newer techniques enable causative von Willebrand factor defects to be identified in more patients than previously, aiding in a specific VWD diagnosis. Genetic analysis can also be helpful in the discrimination between type 2B and platelet-type VWD and in prenatal diagnosis for families with type 3.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27913546      PMCID: PMC6065508          DOI: 10.1182/asheducation-2016.1.678

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  40 in total

1.  Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations.

Authors:  L A O'Brien; J J Sutherland; D F Weaver; D Lillicrap
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

2.  Crucial role for the VWF A1 domain in binding to type IV collagen.

Authors:  Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

3.  Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.

Authors:  Augusto B Federici; Pier M Mannucci; Giancarlo Castaman; Luciano Baronciani; Paolo Bucciarelli; Maria T Canciani; Alessandro Pecci; Peter J Lenting; Philip G De Groot
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

4.  Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Authors:  J Eikenboom; L Hilbert; A S Ribba; A Hommais; D Habart; S Messenger; A Al-Buhairan; A Guilliatt; W Lester; C Mazurier; D Meyer; E Fressinaud; U Budde; K Will; R Schneppenheim; T Obser; O Marggraf; E Eckert; G Castaman; F Rodeghiero; A B Federici; J Batlle; J Goudemand; J Ingerslev; S Lethagen; F Hill; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 5.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 6.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

7.  Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.

Authors:  Maha Othman; Yvette Chirinian; Christine Brown; Colleen Notley; Nicholas Hickson; Daniel Hampshire; Suzanne Buckley; Simon Waddington; Alan L Parker; Andrew Baker; Paula James; David Lillicrap
Journal:  Blood       Date:  2010-08-09       Impact factor: 22.113

8.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

9.  von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.

Authors:  M A Brehm; V Huck; C Aponte-Santamaría; T Obser; S Grässle; F Oyen; U Budde; S Schneppenheim; C Baldauf; F Gräter; S W Schneider; R Schneppenheim
Journal:  Thromb Haemost       Date:  2014-03-06       Impact factor: 5.249

10.  Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.

Authors:  Javier Batlle; Almudena Pérez-Rodríguez; Irene Corrales; Maria Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Ignacia Balda; Carmen Altisent; Rocío Pérez-Montes; Rosa María Fisac; Gemma Iruín; Sonia Herrero; Inmaculada Soto; Beatriz de Rueda; Victor Jiménez-Yuste; Nieves Alonso; Dolores Vilariño; Olga Arija; Rosa Campos; María José Paloma; Nuria Bermejo; Teresa Toll; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Lizheidy Sarmiento; Belén Iñigo; María del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María César; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Rosa Cornudella; Carlos Aguilar; Nina Borràs; Francisco Vidal
Journal:  Thromb Haemost       Date:  2015-08-06       Impact factor: 5.249

View more
  7 in total

1.  Effectiveness and safety of hFVIII/VWF concentrate (Voncento®) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.

Authors:  Lucia Rugeri; Roseline d'Oiron; Annie Harroche; Valérie Proulle; Guillaume Mourey; Emmanuelle De Raucourt; Dominique Desprez; Nathalie Itzhar Baikian; Brigitte Pan Petesch; Annie Borel-Derlon; Sophie Combe; Birgit Frotscher; Abel Hassoun; Hasan Catovic; Diane Bracquart; Marc Trossaërt
Journal:  Blood Transfus       Date:  2020-11-27       Impact factor: 3.443

2.  Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization.

Authors:  Marie-Daniéla Dubois; Ivan Peyron; Olivier-Nicolas Pierre-Louis; Serge Pierre-Louis; Johalène Rabout; Pierre Boisseau; Annika de Jong; Sophie Susen; Jenny Goudemand; Rémi Neviere; Pascal Fuseau; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Caterina Casari
Journal:  Res Pract Thromb Haemost       Date:  2022-06-15

3.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

4.  Case Report: An Infant with Severe Thrombocytopenia Diagnosed with Type 2B von Willebrand Disease Due To a De Novo p.Val1316Met Mutation

Authors:  Junjie Fan; Jing Ling; Huifeng Zhou; Jie He; Shaoyan Hu
Journal:  Turk J Haematol       Date:  2020-07-03       Impact factor: 1.831

5.  Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.

Authors:  Ivana Lapić; Margareta Radić Antolic; Ana Boban; Desiree Coen Herak; Dunja Rogić; Renata Zadro
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

6.  A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD.

Authors:  Qizhen Shi; Scot A Fahs; Jeremy G Mattson; Hongyin Yu; Crystal L Perry; Patricia A Morateck; Jocelyn A Schroeder; Jessica Rapten; Hartmut Weiler; Robert R Montgomery
Journal:  Blood Adv       Date:  2022-05-10

7.  Syntaxin 5 determines Weibel-Palade body size and von Willebrand factor secretion by controlling Golgi architecture.

Authors:  Marije Kat; Ellie Karampini; Arie J Hoogendijk; Petra E Bürgisser; Aat A Mulder; Floris P J Van Alphen; Jenny Olins; Dirk Geerts; Maartje Van den Biggelaar; Coert Margadant; Jan Voorberg; Ruben Bierings
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.